Literature DB >> 18778891

BRAF mutation is associated with the CpG island methylator phenotype in colorectal cancer from young patients.

Pei Woon Ang1, Wei Qi Li, Richie Soong, Barry Iacopetta.   

Abstract

This study investigated the relationship between BRAF mutation, the CpG island methylator phenotype (CIMP+) and APC methylation in colorectal cancer (CRC) from young patients. The V600E BRAF mutation was found in 7% of cases and was strongly associated with the tumour features of proximal site, advanced stage and poor histological grade. More than half (53%) the tumours with BRAF mutation were also CIMP+ as evaluated by a standard panel of markers, compared to only 4% of tumours with wildtype BRAF (P<0.0001). In contrast to CIMP+, APC methylation was inversely correlated with BRAF mutation (P=0.02). BRAF mutation and CIMP+ are therefore likely to be involved in an alternate, albeit rare, pathway to APC inactivation during the development of CRC in younger patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18778891     DOI: 10.1016/j.canlet.2008.08.001

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  9 in total

1.  Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells.

Authors:  Peng Hou; Dingxie Liu; Mingzhao Xing
Journal:  Endocr Relat Cancer       Date:  2011-11-14       Impact factor: 5.678

2.  The BRAF(V600E) causes widespread alterations in gene methylation in the genome of melanoma cells.

Authors:  Peng Hou; Dingxie Liu; Jianli Dong; Mingzhao Xing
Journal:  Cell Cycle       Date:  2012-01-15       Impact factor: 4.534

Review 3.  Lessons from Lynch syndrome: a tumor biology-based approach to familial colorectal cancer.

Authors:  Daniel D Buchanan; Aedan Roberts; Michael D Walsh; Susan Parry; Joanne P Young
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

4.  Dietary, lifestyle and clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study.

Authors:  Adam Naguib; Panagiota N Mitrou; Laura J Gay; James C Cooke; Robert N Luben; Richard Y Ball; Alison McTaggart; Mark J Arends; Sheila A Rodwell
Journal:  BMC Cancer       Date:  2010-03-16       Impact factor: 4.430

Review 5.  BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis.

Authors:  Dong Chen; Jun-Fu Huang; Kai Liu; Li-Qun Zhang; Zhao Yang; Zheng-Ran Chuai; Yun-Xia Wang; Da-Chuan Shi; Qing Huang; Wei-Ling Fu
Journal:  PLoS One       Date:  2014-03-03       Impact factor: 3.240

Review 6.  BRAF mutation is associated with poor clinicopathological outcomes in colorectal cancer: A meta-analysis.

Authors:  Yujie Li; Weier Li
Journal:  Saudi J Gastroenterol       Date:  2017 May-Jun       Impact factor: 2.485

7.  SMAD4 is critical in suppression of BRAF-V600E serrated tumorigenesis.

Authors:  Kevin Tong; Om A Kothari; Katherine S Haro; Anshuman Panda; Manisha M Bandari; Jillian N Carrick; Joseph J Hur; Lanjing Zhang; Chang S Chan; Jinchuan Xing; Michael L Gatza; Shridar Ganesan; Michael P Verzi
Journal:  Oncogene       Date:  2021-08-27       Impact factor: 9.867

8.  Clinical, Pathological, and Molecular Characteristics of CpG Island Methylator Phenotype in Colorectal Cancer: A Systematic Review and Meta-analysis.

Authors:  Shailesh M Advani; Pragati Advani; Stacia M DeSantis; Derek Brown; Helena M VonVille; Michael Lam; Jonathan M Loree; Amir Mehrvarz Sarshekeh; Jan Bressler; David S Lopez; Carrie R Daniel; Michael D Swartz; Scott Kopetz
Journal:  Transl Oncol       Date:  2018-07-30       Impact factor: 4.243

9.  Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer.

Authors:  Shailesh Mahesh Advani; Pragati Shailesh Advani; Derek W Brown; Stacia M DeSantis; Krittiya Korphaisarn; Helena M VonVille; Jan Bressler; David S Lopez; Jennifer S Davis; Carrie R Daniel; Amir Mehrvarz Sarshekeh; Dejana Braithwaite; Michael D Swartz; Scott Kopetz
Journal:  BMC Cancer       Date:  2019-10-17       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.